Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 10Gastrointestinal 7Dermatologic 7CNS 5Head & Neck 4Tumor-Agnostic 3Other solid neoplasm 3Endocrine 3Breast 3Sarcoma 2Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1

Conditions

Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Central Nervous System Neoplasms 1

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × AZD 6244 × Lymphoid × Clear all
NCT03213691 2025-02-05

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 11 charts
CNSLymphoid

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

NCT01278615 2016-02-03

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
16 enrolled 9 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡